E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy.
about
Relative rates of retroviral reverse transcriptase template switching during RNA- and DNA-dependent DNA synthesis.Role of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity.Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelityNovel Tat-encoding bicistronic human immunodeficiency virus type 1-based gene transfer vectors for high-level transgene expression.Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switchingUtilization of nonviral sequences for minus-strand DNA transfer and gene reconstitution during retroviral replication.Recombination between two identical sequences within the same retroviral RNA molecule.Effect of distance between homologous sequences and 3' homology on the frequency of retroviral reverse transcriptase template switching.Development of murine leukemia virus-based self-activating vectors that efficiently delete the selectable drug resistance gene during reverse transcription.Zinc finger domain of murine leukemia virus nucleocapsid protein enhances the rate of viral DNA synthesis in vivo.Effects of varying sequence similarity on the frequency of repeat deletion during reverse transcription of a human immunodeficiency virus type 1 vector.Human immunodeficiency virus type 1 genetic recombination is more frequent than that of Moloney murine leukemia virus despite similar template switching rates.Mechanisms and factors that influence high frequency retroviral recombinationPsi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors.High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replicationDifferential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells.The remarkable frequency of human immunodeficiency virus type 1 genetic recombinationSplit-intron retroviral vectors: enhanced expression with improved safety.Structure-based moloney murine leukemia virus reverse transcriptase mutants with altered intracellular direct-repeat deletion frequencies.Altering the intracellular environment increases the frequency of tandem repeat deletion during Moloney murine leukemia virus reverse transcription.Effects of limiting homology at the site of intermolecular recombinogenic template switching during Moloney murine leukemia virus replicationCorrelated template-switching events during minus-strand DNA synthesis: a mechanism for high negative interference during retroviral recombination.Self-deleting retrovirus vectors for gene therapy.Utilization of nonhomologous minus-strand DNA transfer to generate recombinant retroviruses.Homologous recombination occurs in a distinct retroviral subpopulation and exhibits high negative interference.Development of high-titer retroviral producer cell lines by using Cre-mediated recombination.RRE-deleting self-inactivating and self-activating HIV-1 vectors for improved safety.
P2860
Q33784655-A7F827D4-DA46-49D9-8FF9-83882FABC3B7Q33787219-6DA58E32-327B-4D2D-B12F-4F30165093D5Q33794922-B0D42F2D-5ED1-47E4-BAB2-EE743E2907C2Q33808225-4CB4EAB3-6F91-4C4F-A654-80E19FE558B0Q33809246-3698C1A4-5279-448F-A2AF-E25E7977A7B0Q33811620-53A7D924-6593-4AAB-8A3D-371F6CCFD6E2Q33815788-AC58EDA2-EED9-421F-8894-EA98DB8B6084Q33818586-16CC8D9E-2FC5-46BE-83E9-230D7B461860Q33821435-4971D733-A76A-4DC0-A3D7-57EE70C068ADQ34343761-F5D557F3-F074-442D-A6EB-5C79213842F4Q34343951-070A16B2-311E-482C-84EE-0D13D897B835Q34856375-39A27512-5025-46E4-89CD-B0C8BA16165EQ35276750-AA307094-A308-4B16-AC12-CD5F44F9E361Q35890587-DD4B54C4-0464-44A4-950F-FBAB76F2CECFQ36474197-2D39D22C-615E-4046-8928-C312BA854AFCQ36684758-D6BDE046-DFDB-478A-84EC-089C460A6745Q37333701-18614D64-26DE-4A60-80C5-90DA9603299EQ39589633-36DBF425-E3C3-423C-A35F-EE288463EB80Q39593385-9B15F6E8-36B7-495C-8792-6E4B886F38ECQ39595957-9DCB075C-2EE1-490A-9DA9-89DF6E32715FQ39605230-E384BE81-DA0F-463D-A566-8023AEE80ADDQ39642259-60DA77D6-31F0-4E99-B753-86C68856CB7BQ39875395-BB09DDAE-155C-4F9A-99B2-16AEF6CE97FFQ39878819-74D0E627-D9FE-469E-9876-C661DF27BFB4Q39880572-E41F280C-B55C-449C-805A-135CBDF3849DQ39881544-94AA6347-6839-4C87-85F8-DCA9B40CE912Q42148114-D8D66503-DAF5-458D-847A-1D25062A38DC
P2860
E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
E- vectors: development of nov ...... ectors for safer gene therapy.
@ast
E- vectors: development of nov ...... ectors for safer gene therapy.
@en
type
label
E- vectors: development of nov ...... ectors for safer gene therapy.
@ast
E- vectors: development of nov ...... ectors for safer gene therapy.
@en
prefLabel
E- vectors: development of nov ...... ectors for safer gene therapy.
@ast
E- vectors: development of nov ...... ectors for safer gene therapy.
@en
P2093
P2860
P1433
P1476
E- vectors: development of nov ...... ectors for safer gene therapy.
@en
P2093
P2860
P304
P407
P577
1995-11-01T00:00:00Z